Journal of Mid-life Health Journal of Mid-life Health
Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission | Subscribe | Advertise Users Online: 434  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 




 
 Table of Contents 
CASE REPORT
Year : 2013  |  Volume : 4  |  Issue : 3  |  Page : 188-190  

Lacunar infarction with oral contraceptives: An unusual case report


Department of Pharmacology, V.S.S Medical College and Hospital, Burla, Odisha, India

Date of Web Publication26-Sep-2013

Correspondence Address:
Sasmita Biswal
Associate Professor, Department of Pharmacology, V.S.S Medical College and Hospital, Burla, Odisha
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0976-7800.118996

Rights and Permissions
   Abstract 

Combined oral contraceptives are one of the risk factor for stroke in women. We report a case of an arterial ischemic stroke due to lacunar infarction in a 35-year-old previously healthy female patient induced after 3 years on Sukhi an oral contraceptive after two times artificial abortions. A brain MRI finding was suggestive of lacunar infarction. Her symptoms improved after stopping the oral contraceptive and putting her on I.V heparin therapy.

Keywords: Arterial ischemic stroke, combined oral contraceptives, lacunar infarction, I.V heparin therapy


How to cite this article:
Biswal S. Lacunar infarction with oral contraceptives: An unusual case report. J Mid-life Health 2013;4:188-90

How to cite this URL:
Biswal S. Lacunar infarction with oral contraceptives: An unusual case report. J Mid-life Health [serial online] 2013 [cited 2021 Feb 27];4:188-90. Available from: https://www.jmidlifehealth.org/text.asp?2013/4/3/188/118996


   Introduction Top


Oral contraceptives increase the risk of venous phenomenon due to the hypercoagulable state as a result of their effect on increasing the levels of the circulating coagulation factors. [1] Since their introduction, hormonal contraceptives have always been associated with an increased risk of stroke (cerebrovascular accidents). Thus, thrombotic or ischemic strokes have frequently been associated with the use of oral contraceptives [2] where the risk is directly proportional to the amount of estrogen present in the pill. [3] As the expected risk is presumed to be higher in women who take more than 50 mcg of estrogen per day, physicians hence recommend pills containing 35 mcg of estrogen or less. Thus, the ideal combined oral contraceptive (COC) is the one that contains the lowest amount of estrogen, which in combination with progesterone is effective in preventing pregnancy although minimizing the adverse effects. [4] Hence, all the available COC in the market contain lower doses of estrogen and progesterone than they did in the past, and the current recommendations are to restrict the use of COC to younger women who do not have the associated risk factors for cardiovascular disease.

A common cause of ischemic strokes is lacunar cerebral infarction (LACI) that results from the occlusion of any one of the cerebral penetrating arteries, [5] which accounts for nearly 25% of all ischemic strokes, with an annual incidence of approximately 15/100,000 people. [6] LACI are particularly commonly associated with hypertension and diabetes due to the associated hypercoagulable state. There occur small infarcts either in the basal ganglia, thalamus, and white matter or even in the brain stem. Common symptoms and complications of LACI include anemia, high blood pressure, cerebral infarction, pneumonia, dizziness, cerebral hemorrhage. LACI has usually been seen in uncontrolled hypertension, osteoporosis, arthritis, diabetes and depression. It is also a common adverse effect of certain drugs such as, prednisolone, alendronate, atorvastatin, levothyroxine sodium, etc.

Sukhi is a type of an oral combined contraceptive pill for women that are available in Bangladesh only. [7] Out of the 28 pills in a strip, seven are iron supplements which are brown in colour and the rest of the pills are COC containing Lynestrenol 2.5 mg along with 50 mcg of Ethinyl estradiol per tablet. Although the current recommendation suggests the use of lower doses (30 to 35 μg) of estrogen in oral combined contraceptive pills, Sukhi is the only COC contraceptive that contains high amounts of estrogen. Further, gullible consumers have a wrong notion that Sukhi is a homeopathic contraceptive since the composition of the pill is written in Bengali. For this reason and because of its easy availability as an over the counter drug (OTC) it is also being popularly used in India. Though literature search revealed no documented adverse drug reaction with this COC we report a case of LACI in a 35 year old woman who was on Sukhi for contraception for the last 3 years. To our knowledge, this is the first ever documented case, for there are no such available evidences suggesting such side effects with the otherwise popular combined pill Sukhi.


   Case Report Top


A 35-year-old previously healthy female patient on 'Sukhi' for contraception for the last 3 years presented to the Emergency Department of S.C.B. Medical College and Hospital, Cuttack in November 2011, with complaints of sudden onset (45 min earlier) of slight paralysis of the right side of her body and the inability to express herself by speech, writing, or signs. She was afebrile, alert, oriented with blood pressure of 122/98 mm Hg, pulse rate 100/min. She was a non-smoker, not a known diabetic or hypertensive, but there was history of repeated abortions in the past. General physical examination was normal with normal intact memory. Fundoscopic findings were normal although neurological examination revealed right sided hemiparesis with upward right babinski reflex. On investigations the parameters such as hemogram, ESR, random blood sugar, kidney function tests, liver function tests, electroencephalogram, electrocardiogram, serum cholesterol, serum electrolytes, urine analysis and X-ray chest were within normal limits. Plasma amino acid, vascular profile, and metabolic profile (including levels of homocysteine, ammonia, and lactate) were also within normal limits. Hemoglobin electrophoresis also revealed normal bands. Additional tests such as prothrombin time, activated partial thromboplastin time, antinuclear antibody test, anticardiolipin antibody immunoglobulin levels, protein C level and antithrombin III level were within normal limits.

However a non-contrast enhanced computed tomography of brain showed a LACI [Figure 1] which was confirmed on a magnetic resonance imaging scan. The patient was then hospitalized and treated with intravenous unfractionated heparin, which was then switched on to subcutaneous enoxaparin. After 7 days, her condition completely improved and she was discharged with oral warfarin.
Figure 1: Lacunar Infarction

Click here to view



   Discussion Top


An ischemic stroke results from inadequate blood supply due to occlusion of an artery usually due to thrombus or atherosclerotic plaques. Oral contraceptives, particularly that containing high estrogen dose can increase the risk of thrombus formation. Though studies have shown an increased risk of acute myocardial infarction and hemorrhagic stroke among users of oral contraceptive agents [2],[3] this type of LACI reported in our patient within a span of 3yrs of usage with an oral contraceptive has not been reported so far.

It is well documented that oral contraceptive use increases the risk of venous thromboembolic disease as well as arterial stroke via a mechanism of paradoxical embolism due to a resultant hypercoagulable state. Certain studies have suggested an observed increase in the levels of serum procoagulants such as factor I, VII, VIII, IX, X, XII, and XIII along with a decrease in anticoagulant factors such as protein S and antithrombin III in persons on combined pills. [8]

In addition to the above mentioned mechanisms underlying risk of oral contraceptive-associated venous thromboembolism, there is also an evidence for a genetic susceptibility for oral contraceptive associated stroke. The most susceptible are the women who carry the alleles of the methylene tetrahydrofolate reductase C677T and the factor V Leiden (FV G1691A) genes. [9] Persons with polymorphic forms of the angiotensin-converting enzyme and the angiotensinogen gene may also have increased risk of stroke among women using oral contraceptives. [10] Elevated levels of the factor VII, lipoprotein-associated phospholipase A 2 has also been shown to double the risk of oral contraceptive associated stroke. [11]


   Conclusion Top


Though oral contraceptive drugs are one of the most effective forms of birth control, concern still exists about the short-term and long-term risks associated with these agents. Since the amount of estrogen in oral-contraceptive preparations has been thought to be chiefly responsible for these risks, in recent years newer, low-estrogen oral contraceptives (containing less than 50 μg) have been developed and are widely being used nowadays. Furthermore estrogen-containing hormonal contraception are better avoided among women with a history of cardiovascular disease, including stroke where progestin-only hormonal contraceptives can be used in the setting of stroke. Hence, where oral contraceptives containing the least possible estrogen are recommended and are usually prescribed COC like Sukhi are also irrationally prescribed. Thus, clinicians must always be extra cautious even when prescribing contraceptives for many issues must be taken into account such as the amount of the hormones in them, the genetic pattern of persons thought to be at risk and the rationality of the OTC available COC.

 
   References Top

1.Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996;312:83-8.  Back to cited text no. 1
[PUBMED]    
2.Heyman A, Arons M, Quinn M, Camplong L. The role of oral contraceptive agents in cerebral arterial occlusion. Neurology 1969;19:519-24.  Back to cited text no. 2
[PUBMED]    
3.Gerstman BB, Piper JM, Tornita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991;133:32-7.  Back to cited text no. 3
    
4.Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: Evidence from the Royal College of General Practitioners′ oral contraception study. BMJ 1989; 298:165-8.  Back to cited text no. 4
[PUBMED]    
5.Sacco S, Marini C, Totaro R, Russo T, Cerone D, Carolei A. A population-based study of the incidence and prognosis of lacunar stroke. Neurology 2006;66:1335-8.  Back to cited text no. 5
[PUBMED]    
6.Longstreth WT Jr, Bernick C, Manolio TA, Bryan N, Jungreis CA, Price TR. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: The cardiovascular health study. Arch Neurol 1998;55:1217-25.  Back to cited text no. 6
[PUBMED]    
7.Available from http://www.hindu.com/2007/04/02/stories [Last assessed on 2013 Oct 4].  Back to cited text no. 7
    
8.Winkler UH, Schindler AE, Endrikat J, Dusterberg B. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol. Contraception 1996;53:75-84.  Back to cited text no. 8
    
9.Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, Van Der Graaf Y, Algra A. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost 2005;3:1213-7.  Back to cited text no. 9
[PUBMED]    
10.Li Y, Chen F, Zhou L, Coulter D, Chen C, Sun Z, et al. COC use, ACE/AGT gene polymorphisms, and risk of stroke. Pharmacogenet Genomics 2010;20:298-306.  Back to cited text no. 10
[PUBMED]    
11.Bloemenkamp KW, de Maat MP, Dersjant-Roorda MC, Helmerhorst FM, Kluft C. Genetic polymorphisms modify the response of factor VII to oral contraceptive use: An example of gene-environment interaction. Vascul Pharmacol 2002;39:131-6.  Back to cited text no. 11
[PUBMED]    


    Figures

  [Figure 1]



 

Top
  
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
   Case Report
   Discussion
   Conclusion
    References
    Article Figures

 Article Access Statistics
    Viewed2679    
    Printed110    
    Emailed0    
    PDF Downloaded259    
    Comments [Add]    

Recommend this journal